CA2900529A1 - Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma - Google Patents

Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma Download PDF

Info

Publication number
CA2900529A1
CA2900529A1 CA2900529A CA2900529A CA2900529A1 CA 2900529 A1 CA2900529 A1 CA 2900529A1 CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A1 CA2900529 A1 CA 2900529A1
Authority
CA
Canada
Prior art keywords
fragment
biological sample
subject
bcma
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2900529A
Other languages
English (en)
French (fr)
Inventor
James R. Berenson
Haiming Chen
Eric Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST MYELOMA & BONE CANCER RES
Original Assignee
INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH filed Critical INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH
Publication of CA2900529A1 publication Critical patent/CA2900529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57505—
    • G01N33/57557—
    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2900529A 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma Abandoned CA2900529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762753P 2013-02-08 2013-02-08
US61/762,753 2013-02-08
PCT/US2014/015338 WO2014124280A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Publications (1)

Publication Number Publication Date
CA2900529A1 true CA2900529A1 (en) 2014-08-14

Family

ID=51300158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900529A Abandoned CA2900529A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Country Status (5)

Country Link
US (2) US10126301B2 (show.php)
EP (1) EP2954330A4 (show.php)
JP (2) JP2016507066A (show.php)
CA (1) CA2900529A1 (show.php)
WO (1) WO2014124280A1 (show.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA
BR112018008799A2 (pt) * 2015-10-30 2019-01-15 Glaxosmithkline Intellectual Property Development Limited método de prognóstico
EP3402515B8 (en) * 2016-01-12 2021-12-08 Oncotracker, Inc. Improved methods for monitoring immune status of a subject
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3589952A4 (en) * 2017-02-28 2021-03-10 Menarini Silicon Biosystems S.p.A. IMPROVED KITS AND TESTS FOR DETECTING CIRCULATING MULTIPLE MYELOMA CELLS FROM BLOOD
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
ES2644580B2 (es) * 2017-07-26 2018-06-04 Universitat Politècnica De València Procedimiento de diagnóstico de lupus eritematoso sistémico (les)
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7233425B2 (ja) 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020043868A1 (en) * 2018-08-31 2020-03-05 F. Hoffmann-La Roche Ag Thymidine kinase (tk-1) in prognostic indices for dlbcl
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE69733694T2 (de) 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
CA2459890A1 (en) 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
AU2004220078A1 (en) 2003-03-07 2004-09-23 Xencor, Inc BAFF mutants with at least one amino acid substitution and methods of their production
WO2006025345A1 (ja) 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
WO2006044582A2 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
WO2007053732A2 (en) * 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
US8202698B2 (en) * 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
HUE025173T2 (hu) 2005-12-13 2016-01-28 Incyte Corp Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2198863A1 (en) 2006-02-27 2010-06-23 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
SI3415531T1 (sl) * 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA
EP3102238A1 (en) 2014-01-20 2016-12-14 Gilead Sciences, Inc. Therapies for treating cancers
KR102632731B1 (ko) 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CA2969870A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
ES2883249T3 (es) 2015-03-17 2021-12-07 Mayo Found Medical Education & Res Métodos y materiales para evaluar y tratar el cáncer
KR20180033232A (ko) 2015-07-24 2018-04-02 온코트랙커 인코포레이티드 면역계 기능장애의 치료를 위한 감마 세크레타제 조절제
CN108350076B (zh) 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
BR112018008799A2 (pt) 2015-10-30 2019-01-15 Glaxosmithkline Intellectual Property Development Limited método de prognóstico
EP3402515B8 (en) 2016-01-12 2021-12-08 Oncotracker, Inc. Improved methods for monitoring immune status of a subject
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US20220000872A1 (en) 2018-10-31 2022-01-06 Oncotracker, Inc. Method of enhancing immune-based therapy

Also Published As

Publication number Publication date
JP2016507066A (ja) 2016-03-07
US12174189B2 (en) 2024-12-24
EP2954330A1 (en) 2015-12-16
US10126301B2 (en) 2018-11-13
JP2018136344A (ja) 2018-08-30
EP2954330A4 (en) 2016-08-31
US20190107541A1 (en) 2019-04-11
WO2014124280A1 (en) 2014-08-14
US20160131654A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
EP3402515B1 (en) Improved methods for monitoring immune status of a subject
AU2014266223B2 (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US20180074074A1 (en) Homogenous and heterogeneous assays and systems for determination of ocular biomarkers
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
EP3639028B1 (en) Diagnostic, prognostic, and monitoring methods for breast cancer
DK2551673T3 (en) Methods for detecting cancer infiltration in the central nervous system
CN106290812A (zh) B细胞恶性肿瘤相关抗原表达量检测试剂盒及检测方法
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
ES2939143T3 (es) Biomarcadores para una politerapia que comprende lenvatinib y everolimus
CA3010019C (en) Improved methods for monitoring immune status of a subject
HK40082699A (en) Improved methods for monitoring immune status of a subject
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
CN112639475A (zh) Dlbcl的预后指数中的胸苷激酶(tk-1)
WO2025195496A1 (en) Immunotherapy for ox40 expressing cancer
JP2020509374A (ja) 早期膵がん検出アッセイ
KR20150037321A (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
WO2015151056A2 (en) Mab-fcrn assay

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200207